|R. Shrotriya, Chief Executive Officer|
Spectrum Pharmaceuticals is an American biopharmaceutical company. The company is located in Irvine, California.
In the US, Spectrum markets Fusilev, Folotyn, Marqibo, and Zevalin.
Folotyn (pralatrexate) is marketed for relapsed or refractory Peripheral T-cell lymphoma.
Zevalin (Ibritumomab, Tiuxetan), as part of the Zevalin therapeutic regimen, is indicated for the treatment of patients with relapsed or refractory, low‑grade or follicular B‑cell non‑Hodgkin's lymphoma (NHL), including patients with rituximab refractory follicular NHL. It has been approved by the FDA in 2002.
Marqibo (Vincristine sulfate liposomes injection) is a novel, sphingomyelin/cholesterol liposome-encapsulated formulation of the FDA-approved anticancer drug vincristine. Marqibo's approved indication is for the treatment of adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia (Ph- ALL) in second or greater relapse or whose disease has progressed following two or more lines of anti-leukemia therapy. It had been approved by the FDA in 2012.
A number of drugs are currently investigated in clinical trials.
EOquin (Apaziquone) is a synthetic bio-reductive prodrug intended for the treatment of non-invasive bladder cancer that is currently in Phase 3 studies. Allergan has invested money in 2008 to help develop this medication further and bring it to the market. In Phase 2 studies are Ozarelix, for the treatment of prostate cancer and benign prostatic hypertrophy, Ortataxel, for the treatment of taxane-refractory tumors, and Satraplatin,for non-small cell lung cancer (NSCLC).
Other medications are in development or Phase 1 studies.
- Clinical trials
- Marcial G. "Cancer drugs from Spectrum". Businessweek, June 15, 2009: 67.